TECH OUTLOOK 6DECEMBER - 2021TECH OUTLOOKEditorialStacey Smith Editor-in-Chiefeditor@pharmatechoutlook.comAmid the economic upheaval and supply chain distress over the last two years, big pharma companies have been shifting a significant chunk of their drug discovery work to contract research organisations (CROs). Hence, the demand for CROs has risen manifold. Besides, an increase in investments from both the private and the government sectors is further supporting such outsourced research initiatives in pharma. The primary cause behind this is the emergence of distinct and novel variants of certain diseases. Against the new diseases, CROs can provide innovative ideas and technologies to scale production within in a cost-effective and regulatory compliant manner. In addition, CROs can also enable smarter decision making with the help of invaluable insights derived from volumes of data and help in proactive disease detection by leveraging artificial intelligence (AI) and machine learning (ML) capabilities. They are also proving very crucial in transforming overall sales and marketing outcomes in the pharma domain.When all things are considered, there is no doubt that CROs are on the fast track of evolution. Standing at the cusp of emerging innovations, there is a wide range of solution providers that offer the latest technologies best suited for the next generation of pharma needs. In this edition of Pharma Tech Outlook Europe, we bring you the story of some of the best-of-breed CROs that deliver the best outcomes for their clients. This edition also offers a combination of thought leadership from subject matter experts and exclusive insights from CXOs. We hope this edition will provide you with the right assistance in choosing the best CROs according to your requirements. Let us know your thoughts!Creating a Collaborative Drug Development Environment with CROsCopyright © 2021 ValleyMedia, Inc. All rights reserved. Reproduction in whole or part of any text, photography or illustrations without written permission from the publisher is prohibited. The publisher assumes no responsibility for unsolicited manuscripts, photographs or illustrations. Views and opinions expressed in this publication are not necessarily those of the magazine and accordingly, no liability is assumed by the publisher thereof.DECEMBER - 01 - 2021, Vol 07 - Issue 05 (ISSN 2644-2787) Published by ValleyMedia, Inc. To subscribe to Pharma Tech OutlookVisit www.pharmatechoutlook.com *Some of the Insights are based on the interviews with respective CIOs and CXOs to our editorial staffEditor-in-ChiefStacey SmithVisualizerRonald DonovanAsher BlakeEditorial StaffAaron Pierce Ava GarciaJenna VegasCarolynn Walters Justin SmithPaul BarberSalesBrian Thomasbrian@pharmatechoutlook.comPhone: 510.556.2402sales@pharmatechoutlook.comeditor@pharmatechoutlook.commarketing@pharmatechoutlook.comEmail:Contact Us:Phone:510.556.2402, Fax:510-894-8405TECH OUTLOOK
< Page 5 | Page 7 >